SCHEMBL4618360

SCHEMBL4618360

CC[CH]CC(CC)CC

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5826744 0.83 ALDH1A1 (0.32)
SCHEMBL28406577 0.83
SCHEMBL1644199 0.81
SCHEMBL4920279 0.79 ALDH1A1 (0.50)
SCHEMBL28198758 0.79
SCHEMBL9210989 0.75 LMNA (0.46)
SCHEMBL27469605 0.75
SCHEMBL28037234 0.75 TSHR (0.32)
SCHEMBL304826 0.73 ALDH1A1 (0.33)
SCHEMBL2761586 0.73

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10202322-B2 Resorcinol derivatives SUTTER BAY HOSPITALS (US) 2019-02-12 US claimed
US-20180170846-A1 RESORCINOL DERIVATIVES SUTTER WEST BAY HOSPITALS 2018-06-21 US claimed
EP-2433937-B1 Substituted-quinoxaline-type-piperidine compounds and the uses thereof PURDUE PHARMA LP (US) 2016-06-29 EP claimed
EP-2086958-B1 SUBSTITUTED-QUINOXALINE-TYPE-PIPERIDINE COMPOUNDS AND THE USES THEREOF PURDUE PHARMA LP (US) 2015-01-14 EP claimed
US-20130209483-A1 CANNABIDINOID DERIVATIVES SUTTER WEST BAY HOSPITALS (US) 2013-08-15 US claimed
EP-4175639-A1 MASITINIB FOR THE TREATMENT OF CASTRATE-RESISTANT PROSTATE CANCER AB Science (FR) 2023-05-10 EP disclosed
WO-2022212638-A1 PRODRUGS OF ADAMTS INHIBITORS, PREPARATION METHODS AND MEDICINAL USES THEREOF JIANGSU HENGRUI PHARMACEUTICALS CO., LTD. (CN) 2022-10-06 WO disclosed
WO-2021099616-A1 MASITINIB FOR THE TREATMENT OF SICKLE CELL DISEASE AB SCIENCE (FR) 2021-05-27 WO disclosed
US-10202322-B2 Resorcinol derivatives SUTTER BAY HOSPITALS (US) 2019-02-12 US disclosed
US-20180170846-A1 RESORCINOL DERIVATIVES SUTTER WEST BAY HOSPITALS 2018-06-21 US disclosed
CN-107344980-A Catalytic component, catalyst system and its application for olefinic polymerization 中国石油化工股份有限公司 2017-11-14 CN disclosed
CN-107344976-A Catalytic component, catalyst system and its application for olefinic polymerization 中国石油化工股份有限公司 2017-11-14 CN disclosed
US-20070275448-A1 Methods For Obtaining Optically Active Epoxides And Vicinal Diols From Meso-Epoxides CSIR (ZA) 2007-11-29 US disclosed
WO-2007069079-A2 METHODS FOR OBTAINING OPTICALLY ACTIVE EPOXIDES AND DIOLS FROM 2,3-DISUBSTITUTED AND 2,3-TRISUBSTITUTED EPOXIDES CSIR (US) 2007-06-21 WO disclosed
EP-1756271-A2 METHODS FOR OBTAINING OPTICALLY ACTIVE EPOXIDES AND VICINAL DIOLS FROM 2,2-DISUBSTITUTED EPOXIDES CSIR (ZA) 2007-02-28 EP disclosed
EP-1753862-A2 METHODS FOR OBTAINING OPTICALLY ACTIVE EPOXIDES AND VICINAL DIOLS FROM MESO-EPOXIDES CSIR (ZA) 2007-02-21 EP disclosed
WO-2006109198-A2 METHODS FOR OBTAINING OPTICALLY ACTIVE GLYCIDYL ETHERS AND OPTICALLY ACTIVE VICINAL DIOLS FROM RACEMIC SUBSTRATES OXYRANE UK LIMITED (GB) 2006-10-19 WO disclosed
WO-2005100587-A2 METHODS FOR OBTAINING OPTICALLY ACTIVE EPOXIDES AND VICINAL DIOLS FROM 2,2-DISUBSTITUTED EPOXIDES CSIR (ZA) 2005-10-27 WO disclosed
WO-2005100578-A2 METHODS FOR OBTAINING OPTICALLY ACTIVE EPOXIDES AND VICINAL DIOLS FROM MESO-EPOXIDES CSIR (ZA) 2005-10-27 WO disclosed
EP-0176161-A1 Novel fluoran compounds and production and use thereof TAOKA CHEMICAL CO., LTD (JP) 1986-04-02 EP disclosed